Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI

Inclusion Criteria: * Must be 18 years of age or older and capable of providing informed consent indicating awareness of the investigational nature of this trial, in keeping with institutional policy * Must consent to participate in the trial and have signed an approved informed consent form conforming to institutional policy * Must have histopathologically or cytologically confirmed colon, rectal or appendiceal adenocarcinoma with synchronous or metachronous peritoneal dissemination of disease.(Stage IV peritoneal based disease only) * Must have active measurable disease by either abdominal computerized axial tomography (CT)/ Magnetic resonance imaging (MRI) or laparoscopy. Adequate laboratory values * Absolute neutrophil count (ANC) \> 1200/10\*3/uL * Platelet count \> 140,000/10\*3/uL * Total serum bilirubin ≤ 1.5 mg/dl (patients with total bilirubin \>1.5 mg/dL are eligible only with Gilbert's syndrome) * Alkaline phosphatase \< 2.5 times the upper limit of normal (ULN) (alkaline phosphatase and AST cannot both exceed the ULN) * Aspartate aminotransferase (AST) \< 1.5 times the ULN (alkaline phosphatase and AST cannot both exceed the ULN) * Serum renal function parameters (BUN and creatinine) are within normal limits (eGFR) \>50) * Satisfactory cardiopulmonary function (as determined by Physician) * Patients can have received prior systemic chemotherapy, radiation or surgery * Patients must be able to undergo placement of an intraperitoneal (IP) catheter and a Port-A Cath, if not already present * Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less * Women of reproductive age and men who are sexually active must be willing to practice effective contraception * Patients will be allowed to have secondary malignancies as long as they do not require active concomitant treatment